NZ594365A - Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders - Google Patents
Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disordersInfo
- Publication number
- NZ594365A NZ594365A NZ59436510A NZ59436510A NZ594365A NZ 594365 A NZ594365 A NZ 594365A NZ 59436510 A NZ59436510 A NZ 59436510A NZ 59436510 A NZ59436510 A NZ 59436510A NZ 594365 A NZ594365 A NZ 594365A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mir
- disorders
- treatment
- dual targeting
- cardiac
- Prior art date
Links
- 108091071651 miR-208 stem-loop Proteins 0.000 title abstract 2
- 108091084446 miR-208a stem-loop Proteins 0.000 title abstract 2
- 108091062547 miR-208a-1 stem-loop Proteins 0.000 title abstract 2
- 108091055375 miR-208a-2 stem-loop Proteins 0.000 title abstract 2
- 108091047268 miR-208b stem-loop Proteins 0.000 title abstract 2
- 108091056170 miR-499 stem-loop Proteins 0.000 title abstract 2
- 108091050885 miR-499-1 stem-loop Proteins 0.000 title abstract 2
- 108091038523 miR-499-2 stem-loop Proteins 0.000 title abstract 2
- 208000020446 Cardiac disease Diseases 0.000 title 1
- 208000023178 Musculoskeletal disease Diseases 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000003938 response to stress Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14991509P | 2009-02-04 | 2009-02-04 | |
| PCT/US2010/023234 WO2010091204A1 (en) | 2009-02-04 | 2010-02-04 | Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ594365A true NZ594365A (en) | 2013-03-28 |
Family
ID=42542383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ59436510A NZ594365A (en) | 2009-02-04 | 2010-02-04 | Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8629119B2 (enExample) |
| EP (1) | EP2393945A4 (enExample) |
| JP (1) | JP5943608B2 (enExample) |
| KR (1) | KR20110128838A (enExample) |
| CN (1) | CN102356162A (enExample) |
| AU (1) | AU2010210605B2 (enExample) |
| BR (1) | BRPI1008517A2 (enExample) |
| CA (1) | CA2751489A1 (enExample) |
| MX (1) | MX2011008190A (enExample) |
| NZ (1) | NZ594365A (enExample) |
| RU (1) | RU2515926C2 (enExample) |
| UA (1) | UA105029C2 (enExample) |
| WO (1) | WO2010091204A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9416360B2 (en) | 2010-11-05 | 2016-08-16 | MiRagen Therapeutics, Inc. | Base modified oligonucleotides |
| CA2818174A1 (en) * | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions |
| WO2012083005A2 (en) * | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| KR20140091688A (ko) | 2011-10-06 | 2014-07-22 | 미라젠 세러퓨틱스 인코포레이티드 | 마이크로rna 조절에 의한 전신 에너지 항상성의 제어 |
| EP2584040A1 (en) | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Compounds for treatment of ischemic injury |
| CA2876180C (en) * | 2012-06-21 | 2019-11-19 | MiRagen Therapeutics, Inc. | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
| CN102980920A (zh) * | 2012-11-14 | 2013-03-20 | 华东师范大学 | 同时检测miRNAs与蛋白标记物的硅纳米线芯片及其检测方法和应用 |
| CN105154445B (zh) * | 2014-06-12 | 2018-07-27 | 中国科学院上海生命科学研究院 | 新的肌营养不良肌病的血清miRNA标志物 |
| AR101449A1 (es) * | 2014-08-04 | 2016-12-21 | Miragen Therapeutics Inc | Inhibidores de myh7b y usos de los mismos |
| SG11201705907XA (en) | 2015-01-20 | 2017-08-30 | Miragen Therapeutics Inc | Mir-92 inhibitors and uses thereof |
| EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| JP6721252B2 (ja) * | 2015-06-05 | 2020-07-08 | ミラゲン セラピューティクス， インコーポレイテッド | 皮膚Ｔ細胞リンパ腫（ＣＴＣＬ）を処置するためのｍｉＲ−１５５阻害剤 |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| US12297253B2 (en) | 2018-01-03 | 2025-05-13 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN108815535B (zh) * | 2018-08-08 | 2020-05-19 | 哈尔滨医科大学 | 一种抗心肌肌钙蛋白抗体修饰并载有miR-21的脂质体及其制备方法和应用 |
| CN119246849B (zh) * | 2024-12-09 | 2025-03-14 | 上海基灵生物科技有限公司 | 一种检测犬心脏损伤的试剂盒及应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1364049A2 (en) | 2000-07-31 | 2003-11-26 | Gene Logic, Inc. | Molecular toxicology modeling |
| CN1466463A (zh) * | 2000-09-13 | 2004-01-07 | 中外制药株式会社 | 缺血性疾病治疗剂 |
| WO2002046220A2 (en) * | 2000-12-07 | 2002-06-13 | Gencell S.A. | Sequences upstream of the carp gene, vectors containing them and uses thereof |
| US20050124568A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
| US6964950B2 (en) * | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| WO2003029459A2 (en) | 2001-09-28 | 2003-04-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Micro-rna molecules |
| EP1578393A4 (en) | 2002-02-04 | 2008-03-19 | Gene Logic Inc | MODELING THE TOXICITY OF PRIMARY RAT-BASED RAT CELLS |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US7781415B2 (en) | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| WO2005078096A2 (en) | 2004-02-09 | 2005-08-25 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| CA2554818A1 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
| CA2556435C (en) | 2004-02-13 | 2014-08-12 | The Rockefeller University | Anti-microrna oligonucleotide molecules |
| EP2290070B1 (en) | 2004-05-28 | 2015-03-25 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| WO2006013561A2 (en) | 2004-08-02 | 2006-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for diagnosing and treating post traumatic stress disorder |
| JP2006101790A (ja) | 2004-10-06 | 2006-04-20 | Japan Health Science Foundation | 高血圧症のリスクの評価方法 |
| US20080269072A1 (en) | 2004-10-21 | 2008-10-30 | Hart Ronald P | Rational Probe Optimization for Detection of MicroRNAs |
| ES2534302T3 (es) * | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| US9550990B2 (en) | 2004-12-10 | 2017-01-24 | Ionis Pharmaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| EP1838870A2 (en) | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| CN101203611B (zh) | 2005-04-19 | 2013-08-14 | 巴斯福植物科学有限公司 | 控制基因表达的改良方法 |
| HUE027013T2 (en) | 2005-05-27 | 2016-10-28 | Ospedale San Raffaele Srl | A gene vector containing MI-RNA |
| WO2007035684A2 (en) | 2005-09-16 | 2007-03-29 | Primera Biosystems, Inc. | Method for quantitative detection of short rna molecules |
| US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| NZ569738A (en) | 2005-12-12 | 2012-03-30 | Univ North Carolina | MicroRNAs (miRNA) that regulate muscle cell proliferation and differentiation |
| US20100286044A1 (en) | 2005-12-29 | 2010-11-11 | Exiqon A/S | Detection of tissue origin of cancer |
| AU2007211082B2 (en) | 2006-01-27 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| MX2009001281A (es) * | 2006-08-01 | 2009-04-16 | Univ Texas | Identificacion de un micro-arn que activa la expresion de la cadena pesada de beta-miosina. |
| US20090306181A1 (en) | 2006-09-29 | 2009-12-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| EP2476762B1 (de) | 2006-10-09 | 2014-01-08 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen |
| US20100021914A1 (en) | 2006-11-23 | 2010-01-28 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
| CN102604951A (zh) | 2006-12-14 | 2012-07-25 | 诺瓦提斯公司 | 治疗肌肉和心血管病症的组合物和方法 |
| WO2008074328A2 (en) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| WO2008147839A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| CA2694928A1 (en) * | 2007-07-31 | 2009-02-05 | Board Of Regents, The University Of Texas System | Micro-rnas that control myosin expression and myofiber identity |
| US20100292099A1 (en) | 2007-08-23 | 2010-11-18 | Keren Pharmaceutical, Inc. | Targeting of rna with external guide sequences |
| KR101889518B1 (ko) | 2007-10-04 | 2018-08-17 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 마이크로ＭＩＲｓ |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| CN101951924B (zh) | 2007-11-09 | 2015-06-24 | 得克萨斯系统大学董事会 | Mir-15家族的微小rna调控心肌细胞存活和心脏修复 |
| US20110160285A1 (en) | 2008-03-13 | 2011-06-30 | The Regents Of The University Of Colorado | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| AU2009256243A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
| EP2303292A4 (en) | 2008-06-09 | 2013-01-02 | New York Medical College | COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC |
| EP2358398A2 (en) | 2008-10-24 | 2011-08-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
-
2010
- 2010-02-04 JP JP2011548431A patent/JP5943608B2/ja not_active Expired - Fee Related
- 2010-02-04 BR BRPI1008517A patent/BRPI1008517A2/pt not_active IP Right Cessation
- 2010-02-04 MX MX2011008190A patent/MX2011008190A/es active IP Right Grant
- 2010-02-04 CN CN2010800123730A patent/CN102356162A/zh active Pending
- 2010-02-04 WO PCT/US2010/023234 patent/WO2010091204A1/en not_active Ceased
- 2010-02-04 NZ NZ59436510A patent/NZ594365A/xx not_active IP Right Cessation
- 2010-02-04 KR KR20117020396A patent/KR20110128838A/ko not_active Ceased
- 2010-02-04 AU AU2010210605A patent/AU2010210605B2/en not_active Ceased
- 2010-02-04 CA CA 2751489 patent/CA2751489A1/en not_active Abandoned
- 2010-02-04 US US13/147,784 patent/US8629119B2/en not_active Expired - Fee Related
- 2010-02-04 UA UAA201110646A patent/UA105029C2/uk unknown
- 2010-02-04 RU RU2011136640/10A patent/RU2515926C2/ru not_active IP Right Cessation
- 2010-02-04 EP EP20100739137 patent/EP2393945A4/en not_active Withdrawn
-
2013
- 2013-12-12 US US14/104,886 patent/US20140179764A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2393945A1 (en) | 2011-12-14 |
| RU2011136640A (ru) | 2013-03-10 |
| CA2751489A1 (en) | 2010-08-12 |
| JP2012516856A (ja) | 2012-07-26 |
| CN102356162A (zh) | 2012-02-15 |
| JP5943608B2 (ja) | 2016-07-05 |
| BRPI1008517A2 (pt) | 2016-03-08 |
| AU2010210605B2 (en) | 2015-08-13 |
| UA105029C2 (uk) | 2014-04-10 |
| EP2393945A4 (en) | 2013-08-07 |
| KR20110128838A (ko) | 2011-11-30 |
| US20140179764A1 (en) | 2014-06-26 |
| WO2010091204A1 (en) | 2010-08-12 |
| MX2011008190A (es) | 2011-10-06 |
| US8629119B2 (en) | 2014-01-14 |
| RU2515926C2 (ru) | 2014-05-20 |
| AU2010210605A1 (en) | 2011-08-25 |
| US20120035243A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ594365A (en) | Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| TN2012000428A1 (en) | Bisaryl-bonded aryltriazolones and use thereof | |
| MX350761B (es) | Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa. | |
| MX351464B (es) | El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas. | |
| MD4601B1 (ro) | Inhibitor al kinazei inductoare de apoptoză | |
| MY173994A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| UA115320C2 (uk) | Інгібітори кінази | |
| PH12012502162A1 (en) | Combination therapy | |
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| TN2012000280A1 (en) | Methods of administering pirfenidone therapy | |
| GEP20156347B (en) | Benzodioxane inhibitors of leukotriene production | |
| MX2014002393A (es) | Inhibidores de rock suaves, novedosos. | |
| EP2582682A4 (en) | METHOD FOR THE TREATMENT OF LUNG DISEASES | |
| PH12012502129A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| MX2011011109A (es) | Formulaciones orales de bendamustina. | |
| TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
| MX2009010485A (es) | Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas. | |
| MY175764A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| PH12012501389A1 (en) | Hedgehog inhibitors | |
| PH12013501163A1 (en) | Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 FEB 2017 BY CPA GLOBAL Effective date: 20131219 |
|
| LAPS | Patent lapsed |